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Summary The inheritance of most forms of epilepsy is usually considered to be
multifactorial, although a number of single gene causes are known. Most previous
studies of epilepsy genetics have implicated ion channel genes or ligand receptors. In
a previous study of children with adverse effects of prenatal exposure to antiepileptic
drugs, we noted an increased frequency of the methylene tetrahydrofolate reductase
(MTHFR) 677C>T polymorphism in the mothers. To investigate this further, a new
cohort of women with epilepsy has been identified from maternity hospital records
and genotyped for polymorphisms in MTHFR, serine hydroxymethyl transferase
(SHMT1), methionine synthase (MTR) and methionine synthase reductase (MTRR).
Healthy blood donors were genotyped as controls. The frequency of theMTHFR 677TT
genotype was significantly higher in women with idiopathic generalised epilepsy than
in healthy controls ( p = 0.012, OR 2.26, 95%CI 1.13—4.51). No association was
detected for the other polymorphisms tested. The MTHFR 677C>T polymorphism
may be a susceptibility factor for epilepsy, and its higher frequency in women with
epilepsy may contribute to the increased risk of malformation in children of women
with epilepsy.
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Epilepsy is a common disorder affecting around 5 per
1000 individuals under the age of 64.1 It is pheno-
typically and aetiologically heterogeneous. If there
is evidence of brain injury, tumour, or an underlying
disorder affecting the brain such as tuberous sclero-
sis, the epilepsy may be classified as symptomatic or
secondary. Often, no brain lesion can be identified,
and the epilepsy is said to be ‘‘idiopathic’’.2—4
Inherited forms of idiopathic epilepsy due to muta-
tion in a single gene have been identified, but
familial recurrence rates for idiopathic epilepsies
in general, and the heterogeneity of epilepsy phe-
notype within families suggest complex inheritance
(involvement of many genes and probably non-
genetic factors). Genome-wide scans and other stu-
dies aimed at finding susceptibility genes for idio-
pathic epilepsy, have implicatedmostly ion channel,
and ligand receptor genes.4 Two small studies also
showed an association between the common
677C>T polymorphism in the methylene tetrahydo-
folate reductase (MTHFR) gene and epilepsy.5,6 In a
previous study,7 we found an apparent association
between maternal MTHFR genotype and serious
adverse effects in the child of prenatal antiepileptic
drug (AED) exposure, but as there was no control
group of normal children with prenatal AED expo-
sure, the association detected could have been with
maternal epilepsy. Although most of the mothers
had epilepsy, a few had been prescribed AEDs for
other disorders. In order to investigate whether
MTHFR or other folate pathway gene polymorphisms
are associated with epilepsy, we undertook a further
study in a population-based cohort of women with
epilepsy ascertained through Aberdeen Maternity
Hospital records and report the findings.Methods
Clinical recruitment and classification
In North-East Scotland, high risk pregnancies
(including those in women with epilepsy) are man-
aged at Aberdeen Maternity Hospital. Four hundred
and eighty-six mothers who were prescribed AEDs
during a pregnancy between 1 January 1976 and 31
December 2002 were identified from hospital
records.8 Of these, 333 were contactable, and
200 agreed to participate. A trained research nurse
undertook structured interviews recording maternal
medical history, family history, and AED use in each
pregnancy. Epilepsy diagnosis and investigations
were reviewed in the hospital records. Epilepsy
classification followed the principles outlined byScheffer and Berkovic–—where medical history or
brain imaging suggested a possible brain injury, then
epilepsy was classified as symptomatic, otherwise it
was classified as idiopathic. DNAwas extracted from
blood or mouth brush samples taken from 174
mothers. AEDs were prescribed for epilepsy in 170
mothers sampled, and for bipolar illness in 4.
DNA samples from 312 healthy age matched
female blood donors from North-East Scotland
(mean age 29 years, S.D. 11.3) were genotyped as
controls. AED use precludes blood donation, there-
fore this control group does not include individuals
with active epilepsy.
Genotyping
Genomic DNA samples were genotyped for five poly-
morphisms in four genes (MTHFR 677C>T,9 MTHFR
1298A>C,10,11 cytosolic SHMT1 1420C>T,12 MTR
2756A>G,13 MTRR 66A>G14) using published PCR-
restriction digestion methods.
Statistical analysis
Genotype frequencies in mothers with epilepsy
were compared with female healthy blood donor
controls using a case-control study design. Signifi-
cance was assessed using the x2 test or Fisher two-
tailed test and odds ratios with 95% confidence
intervals were calculated. The data for MTHFR
677C>T is subdivided by epilepsy category
(Table 1), whereas data for other genotypes is shown
for idiopathic generalised epilepsy (IGE) only
(Table 2). MTHFR 677C>T/1298A>C haplotypes for
IGE cases and controls were inferred using an online
implementation of a maximum likelihood method
(HAP Version 3, http://research.calit2.net/hap/
WebServer.htm),15 and odds ratios with 95% confi-
dence intervals calculated for haplotypes and diplo-
types (Tables 3 and 4). To check consistency of
haplotype inference, a similar analysis was under-
taken using an alternative algorithm and software
implementation (Phase version 2.116,17), but this
gave similar results (data not shown).
The study was reviewed and approved by the NHS
Grampian Local Research Ethics Committee.Results
The majority of women tested had idiopathic gen-
eralised epilepsy (Table 1). MTHFR 677C>T geno-
type frequencies were significantly different from
controls in this group. The proportion of TT homo-
zygotes and CT heterozygotes was greater than in
controls, and the frequency of TT homozygotes
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Table 1 MTHFR 677C>T genotypes
Epilepsy type MTHFR 677C>T genotype x2test TT and CT vs. CC TT vs. CC
CC CT TT Total p p OR 95% CI p OR 95% CI
Idiopathic Generalised 49 (37%) 62 (47%) 22 (17%) 133 0.029 0.028 1.59 1.03—2.48 0.012 2.26 1.13—4.51
Focal 3 (38%) 5 (62%) 0 8
All 52 (37%) 67 (48%) 22 (16%) 141 0.04 0.026 1.59 1.04—2.45 0.019 2.13 1.07—4.23
Symptomatic Generalised 6 (35%) 9 (53%) 2 (12%) 17
Focal 5 (50%) 3 (50%) 2 (20%) 10
All 11 (41%) 12 (44%) 4 (15%) 27 0.607 0.458 1.35 0.57—3.24 0.3a 1.83 0.4—6.72
GEFS+ 1 1 0 2
All epilepsy 64 (38%) 80 (47%) 26 (15%) 170 0.041 0.027 1.54 1.03—2.3 0.019 2.05 1.07—3.91
Controls 146 (48%) 128 (42%) 29 (10%) 303
a Fisher’s two-tailed test.
Table 2 Case-control study of maternal idiopathic generalised epilepsy and folate pathway genes
Polymorphism Group Genotypes x2 test Comparing rr/Rr with RR Comparing rr with RR
RR Rr rr Total p p OR (95% CI) p OR (95% CI)
MTHFR 677C>T Cases 49 37% 62 47% 22 17% 133 0.029 0.028 1.59 (1.03—2.48) 0.012 2.26 (1.13—4.51)
Controls 146 48% 128 42% 29 10% 303
MTHFR 1298A>C Cases 69 53% 50 39% 10 8% 129 0.353 0.159 0.73 (0.47—1.16) 0.301 0.66 (0.27—1.55)
Controls 109 46% 105 44% 24 10% 238
SHMT1 1420C>T Cases 62 48% 55 43% 11 9% 128 0.18 0.68 0.92 (0.59—1.42) 0.745 0.88 (0.38—2.01)
Controls 129 46% 124 44% 26 9% 279
MTR 2756A>G Cases 91 76% 35 29% 5 4% 120 0.967 0.917 1.02 (0.64—1.64) 0.777a 1.16 (0.3—3.87)
Controls 212 70% 81 27% 10 3% 303
MTRR 66A>G Cases 15 11% 63 48% 42 32% 131 0.537 0.548 1.24 (0.58—2.64) 0.307 1.5 (0.64—3.51)
Controls 23 15% 87 57% 43 28% 153
R = common allele, r = rare allele (e.g., for MTHFR 677C>T, R = C and r = T).
a Fisher’s two-tailed test.
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Table 3 Haplotype analysis of MTHFR 677C>T and 1298A>C polymorphisms for mothers with IGE compared with
controls
Haplotype IGE Controls p value OR 95%CI
677T/1298A 107 40% 184 24% 0.000002 2.08 1.52—2.86
677C/1298A 91 34% 287 46% 0.00851 0.6 0.44—0.82
677C/1298C 70 26% 151 29.5% 0.205 0.81 0.58—1.13
677T/1298C 2 0.5%
Totals 268 624(17%) was significantly different from controls
(10%), compared with CC homozygotes. The idio-
pathic focal epilepsy subgroup is too small for inde-
pendent statistical analysis, but when all idiopathic
epilepsies are considered together, the genotype
frequency differences remain statistically signifi-
cant. MTHFR 677C>T genotype frequencies were
not significantly different from controls in the symp-
tomatic epilepsy subgroup, although numbers were
small. MTHFR 1298A>C, SHMT1 1420C>T, MTR
2756A>G and MTRR 66A>G genotype frequencies
in mothers with idiopathic generalised epilepsy
were not significantly different from healthy female
blood donor controls (Table 2). Inclusion of mothers
with idiopathic focal epilepsies did not significantly
alter these genotype frequencies, and genotype
frequencies in mothers with symptomatic epilepsy
were not significantly different from controls (data
not shown). The control genotype frequencies were
in Hardy—Weinberg equilibrium (MTHFR 677C>T,
p = 0.998, MTHFR 1298A>C, p = 0.986, SHMT1
1420C>T, p = 0.966, MTR 2756A>G, p = 0.867,
MTRR 66A>G, p = 0.373), and were not significantly
different from published frequencies in similar
populations (p values between 0.203 and
0.795).18,10,11,12,14
Haplotype analysis was undertaken for the
MTHFR genotypes in the IGE mothers and controls.
The frequency of the 677T/1298A haplotype wasTable 4 Diplotype analysis of MTHFR 677C>T and 1298A>
controls (TA = 677T/1298A, TA/CC indicates an individual w
1298C on the other–—i.e., both rare alleles are present, and
Diplotypes IGE Contr
TA/TA 22 16.5% 28
CA/TA 37 28% 88
TA/CC 26 19% 39
CA/CA 15 11% 67
CA/CC 24 18% 65
CC/CC 10 7.5% 23
TA/TC 1
CC/TC 1
Totals 134 312
All 677C/C homozygotes 49 37% 155
All 1298A/A homozygotes 74 55% 183significantly greater in IGE cases than controls,
whereas the 677C/1298A haplotype was signifi-
cantly less common in cases (Table 3). Analysing
diplotypes, the frequency of individuals homozy-
gous for both 677T and 1298A was significantly
greater in IGE cases than in controls, and the fre-
quency of individuals homozygous for both common
alleles (677C and 1298A) was significantly lower
(Table 4). Analysing 677CC homozygotes and
1298AA homozygotes independently, the IGE group
had fewer 677CC homozygotes than the control
group (p = 0.01, OR 0.58, 95%CI 0.39—0.9) but there
was no significant difference for 1298AA ( p = 0.501,
OR 0.87, 95%CI 0.57—1.34).Discussion
Although there are a number of monogenic epilepsy
syndromes (for example, autosomal dominant fron-
tal lobe epilepsy, benign familial neonatal seizures)
most forms of idiopathic epilepsy probably have a
polygenic form of inheritance.4 The final epilepsy
phenotype is likely to be influenced by the interac-
tion of several genes, and perhaps non-inherited
factors. Some of these genes may be regarded as
susceptibility genes, and could also affect risk of
developing symptomatic epilepsy after brain injury.
Most studies of epilepsy genetics have concentratedC polymorphisms for mothers with IGE compared with
ith 677T and 1298A on one chromosome, and 677C and
are in trans)
ols p value OR 95%CI
9% 0.0223 1.99 1.05—3.78
28% 0.898 0.97 0.6—1.56
12.5% 0.058 1.69 0.94—3
21.5% 0.01 0.46 0.24—0.87
21% 0.478 0.83 0.48—1.43
7% 0.973 1.01 0.44—2.31
0.5%
0.5%
50% 0.01 0.58 0.39—0.9
59% 0.501 0.87 0.57—1.34
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genes involved in intracellular signalling, or axonal
guidance.4 Genome-wide scans have usually impli-
cated such genes,19,20 although recently one study
implicated a metabolic enzyme, malic enzyme 2 in
non-specific epilepsy susceptibility.21 Two previous
studies have implicated MTHFR as a susceptibility
factor for epilepsy–—one study demonstrated an
excess of MTHFR 677TT homozygotes in men and
women attending an epilepsy clinic in Korea,5 while
the other found an excess of MTHFR 677T alleles
amongst patients with symptomatic epilepsy, but
not in those with idiopathic epilepsy.6 Numbers in
this second study were small. Our genotype fre-
quency results suggest an association between the
MTHFR 677CTand TT genotypes and idiopathic gen-
eralised epilepsy in fertile women, although the
association is still significant when mothers with
symptomatic epilepsy are included (Table 1). Our
data does not show a significant association with
symptomatic epilepsy separately, but the number in
this subgroup is small. Case selection could have
influenced these results, in that our cases were all
mothers, and only 51% of those eligible could be
genotyped successfully. There is no reason to
believe that cases were more or less willing to give
a sample than controls, or that this factor is asso-
ciated with MTHFR genotype, but these possibilities
cannot formally be excluded. Our control group is
age and gender matched to the cases and comes
from a similar ethnic background, but we do not
know their reproductive histories. However, our
study provides similar findings to previous studies
in other groups of patients with epilepsy, which
included males and did not select through an obste-
tric route, suggesting that the association between
MTHFR 677C>T and epilepsy may be real.
The mechanisms behind this association are
unclear. The polymorphism is associated with a
twofold increase in plasma homocysteine in the
homozygous state,9 particularly in those taking
AEDs,5 although unfortunately levels were not mea-
sured in this study. Patients with seizures due to
autosomal recessive MTHFR deficiency have a 10-
fold increase in plasma homocysteine, but also have
leukoencephalopathy and other neurological
abnormalities22–—the contribution of homocysteine
level to seizure risk is uncertain.
Homozygosity for the 677T allele interacts with
dietary folic acid depletion to cause leucocyte
DNA hypomethylation in healthy adults.23—26 Homo-
zygosity for the 1298C allele may not have the
same effect.25,26 Activity-dependent regulation of
expression of the neurotrophin BDNF, thought to
be involved in epilepsy susceptibility, relies on
DNA methylation.27,28 MTHFR 677C>T could affectepilepsy susceptibility by enhancing BDNF expres-
sion inappropriately through DNA hypomethylation.
No association with theMTHFR 1298A>C polymorph-
ism was detected in our study, which is compatible
with this hypothesis.
MTHFR haplotype analysis (Table 3) demon-
strated an association with the 677T allele in cis
with 1298A, and suggests a protective effect of 677C
in cis with 1298A. The occurrence of the two
reduced activity alleles (677T and 1298C) in cis
was not inferred in the cases, and appeared at very
low frequency in the controls. This is compatible
with previous studies suggesting strong linkage dis-
equilibrium (LD) between these two polymorphisms,
which have apparently arisen on different ancestral
chromosomes.11,29 Any weak effect of 1298C could
therefore have been masked by the strong LD with
677T. The diplotype analysis (Table 4) also suggested
an association between IGE and homozygosity for
677T ( p = 0.0223), but did not suggest any signifi-
cant association with homozygosity for 1298C
(p = 0.973), or with compound heterozygosity
(p = 0.058). In addition, although homozygosity
for both 677C and 1298A may have a protective
effect against IGE (p = 0.01), this effect appears
to be due to the 677C allele (p = 0.01).
The apparent association with MTHFR 677C>T
could be due to linkage disequilibrium with another
gene located nearby on chromosome 1p36. Avoltage
gated potassium channel gene, KCNAB2, maps to
chromosome 1p36, and deletion of this region is
associated with infantile spasms30 but other genes
are also lost in the deletion, and the relevance of
KCNAB2 to idiopathic epilepsy is unknown. If the
MTHFR 677C>T polymorphism was acting as a mar-
ker for an adjacent gene, similar effects would
be expected on MTHFR 1298A>C frequency. The
absence of any detectable effect for 1298C using
genotype, haplotype and diplotype analysis suggests
although does not prove that 677T may be causa-
tive.
Genome-wide scans have failed to implicate this
chromosome region in epilepsy susceptibility pre-
viously, but these studies have tended to select
multiplex, multigenerational families, often identi-
fied through a proband with juvenile onset epilepsy
in order to enrich for potentially Mendelian epilepsy,
and used linkage-based methods more adapted to
identifying dominant genes.19—21 Our study did not
deliberately select such families, but the average
onset age of our cases was 14.8 years, and 38% had a
family history of epilepsy, comparable with other
studies. It may be that the effect of homozygosity
for MTHFR 677C>T as a susceptibility factor is
too weak to detect in a conventional linkage
scan–—the only other study identifying a recessive
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Figure 1 BHMT, betaine homocysteine methyl transferase; MAT, methionine adenosyl transferase; MT, methyl trans-
ferase; SAHH, s-adenosyl homocysteine hydrolase; MTHFR, 5,10-methylene tetrahydrofolate reductase; MTR, methio-
nine synthase; MTRR, methionine synthase reductase; DHFR, dihydrofolate reductase; TS, thymidylate synthase; SHMT,
serine hydroxy methyl transferase 1; CH3THF, 5-methyl tetrahydrofolate; THF, tetrahydrofolate; DHF, dihydrofolate;
CH2THF, 5,10-methylene tetrahydrofolate.susceptibility factor for epilepsy (malic enzyme)
also used association-based methods as well as link-
age.21
Although the MTHFR 677C>T polymorphism is
the most widely studied genetic variant in the folate
pathway, variants in other genes affecting folate
metabolism could also contribute. We therefore
chose to test three other polymorphisms in folate
pathway genes for association with epilepsy. A key
role of MTHFR in folate metabolism is to provide the
5-methyltetrahydrofolate required by MTR for the
remethylation of homocysteine to methionine31
(Fig. 1). The 677C>T polymorphism results in a
thermolabile enzyme with reduced activity, while
the second MTHFR polymorphism studied, 1298A>C
causes a milder impairment of enzyme activity.11
MTR activity is controlled by MTRR and, like MTHFR,
common polymorphisms in these genes have been
associated with malformations such as neural tube
defects in children.32 The polymorphisms chosen for
study might be predicted to reduce the availability
of methionine as a substrate for methylation, as well
as increasing homocysteine levels, in a similar way
to MTHFR 677C>T. SHMT1 reversibly catalyses the
production of 5,10-methylene tetrahydrofolate, the
substrate for both MTHFR and thymidylate synthase,
from tetrahydrofolate, and may act as a metabolic
switch betweenmethionine synthesis and thymidine
synthesis.33 The 1420C>T polymorphism in this gene
alters the distribution of folate derivatives.12 The
distributions of genotypes and allele frequencies for
MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G andSHMT1 1420C>T in the women with epilepsy studied
were not significantly different from age matched
controls, providing no evidence that they are
involved in epilepsy susceptibility. This lack of asso-
ciation could be because they cause less interfer-
ence with methionine availability or homocysteine
levels than the MTHFR 677C>T polymorphism, and
measurement of homocystine and methionine levels
in the mothers and controls might have clarified this
point. MTHFR 677C>T, 1298A>C and the MTR and
MTRR polymorphisms all show an association with
neural tube defect in children. Possibly the devel-
oping embryo is more sensitive to perturbations of
this pathway than the adult brain, or perhaps MTHFR
has an additional role in the development or func-
tion of the brain which is yet to be determined.
Including this one, three studies have now impli-
cated the MTHFR 677C>T polymorphism in epilepsy
susceptibility, and the association could provide
part of the explanation for the increased frequency
of malformation in children of mothers with epi-
lepsy.7 Clarification of the degree of risk, implica-
tions for management, and underlying pathogenetic
mechanisms await further studies.Acknowledgements
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